Table 3

		Overall mortality							Mortality from endometrial cancer
	N	Deaths N		5-year survival (95% CI)	Unadjusted HR (95% CI)	P-value	Adjusted HR (95% CI)a	P-value	Deaths N	5-year survival (95% CI)	Unadjusted HR (95% CI)	P-value	Adjusted HR (95% CI) b	P-value
*All patients*
None	87		11	87% (80-94)	1c		1c		5	94% (89-99)	1c		1c
Brachytherapy	94		8	91% (86-97)	0.7 (0.3-1.7)	.388	1.1 (0.4-2.8)	.892	5	94% (90-99)	0.9 (0.3-3.2)	.899	1.3 (0.4-4.8)	.667
External +/- Brachytherapy	89		14	84% (76-92)	1.3 (0.6-2.9)	.480	3.2 (1.2-8.7)	.020	9	89% (82-96)	1.9 (0.6-5.6)	.260	3.6 (1.0-13.4)	.059
*Low risk (myometrial invasion <50%, grade 1-2)*
None	61		6	90% (82-97)	1c		1c		2	97% (92-100)	1c		1c
Brachytherapy	75		5	93% (88-99)	0.7 (0.2-2.2)	.426	1.6 (0.4-1.3))	.476	2	97% (93-100)	0.8 (0.1-5.7)	.832	1.7 (0.2-13.9)	.642
External +/- Brachytherapy	26		4	84% (70-99)	1.7 (0.5-5.9)	.639	6.4 (1.3-30.2)	.020	3	89% (76-100)	3.7 (0.6-22.4)	.149	9.4 (1.0-86.7)	.047
*High risk (myometrial invasion <50%, grade 3 or myometrial invasion >=50%, grade 1-2)*
None	26		5	80% (65-96)	1c		1c		3	87% (74-100)	1c		1c
Brachytherapy	19		3	84% (68-100)	0.8 (0.2-3.5)	.802	1.0 (0.2-4.3)	.973	3	84% (68-100)	1.4 (0.3-6.9)	.682	1.6 (0.3-8.1)	.564
External +/- Brachytherapy	63		10	90% (74-93)	0.9 (0.3-2.5)	.792	1.7 (0.5-6.3)	.396	6	90% (82-98)	0.9 (0.2-3.5)	.838	1.9 (0.4-9.1)	.453

^aAdjusted for age (continuous), tumour risk category and sector of care ^bAdjusted for age (continuous) and tumour risk category ^cReference category

Table 3: Number of deaths, overall and five-year disease-specific survival and all cause mortality and endometrial cancer mortality risks according to type of radiotherapy for low risk and high risk patients.